Physiologically based pharmacokinetic model use in risk assessment-Why being published is not enough

Toxicological Sciences

Volumn 126, Issue 1, 2012, Pages 5-15

  McLanahan, Eva D ^a   El Masri, Hisham A ^b   Sweeney, Lisa M ^c   Kopylev, Leonid Y ^d   Clewell, Harvey J ^e   Wambaugh, John F ^e   Schlosser, P M ^d  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c WRIGHT PATTERSON AIR FORCE BASE   (United States)

^d HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^e U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Benchmark dose; Markov chain Monte Carlo; Ontology; PBPK; Risk assessment

Indexed keywords

ARTICLE; BIOLOGICAL MODEL; COMPUTER LANGUAGE; DOCUMENTATION; DOSIMETRY; EXPERT SYSTEM; HUMAN; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; POPULATION DISTRIBUTION; PROBABILITY; QUALITY CONTROL; RISK ASSESSMENT; TREATMENT RESPONSE;

EID: 84857929643     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr295     Document Type: Article

References (58)

1. Aegis. (2008). acslX User's Guide version 2.4. Available at: http://www.acslx.com/Support&Downloads/Documentation/Users%20Guide.pdf. Accessed May 1, 2011.
2. Akaike, H. (1974). A new look at statistical-model identification. IEEE Trans. Automat. Contr. 19, 716-723.
3. Allen, B. C., Covington, T. R., and Clewell, H. J. (1996). Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology 111, 289-303.
4. Ausbrooks, R., Bos, B., Caprotti, O., Carlisle, D., Chavchanidze, G., Coorg, A., Dalmas, S., Devitt, S., Dooley, S., Hinchclie, M., et al. (2010). Mathematical Markup Language (MathML) Version 3.0 World Wide Web Consortium. Available at: http://www.w3.org/TR/MathML3. Accessed May 1, 2011.
5. Blancato, J. N., and Bischoff, K. B. (1985). Subcellular pharmacokinetics of 2,5-hexanedione. In North American Symposium on Risk Assessment and the Biological Fate of Xenobiotics. International Society for the Study of Xenobiotics, Key Biscayne, FL.
6. Bogen, K. T., and Spear, R. C. (1987). Integrating uncertainty and interindividual variability in environmental risk assessment. Risk Anal. 7, 427-436.
7. Bois, F. Y. (1999). Analysis of PBPK models for risk characterization. Ann. N. Y. Acad. Sci. 895, 317-337.
8. Bois, F. Y. (2000). Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ. Health Perspect. 108(Suppl. 2), 307-316.
9. Bois, F. Y. (2001). Applications of population approaches in toxicology. Toxicol. Lett. 120, 385-394.
10. Bois, F.Y., Gelman, A., Jiang, J., Maszle, D.R., Zeise, L., andAlexeef, G. (1996a). Population toxicokinetics of tetrachloroethylene. Arch. Toxicol. 70, 347-355.
11. Bois, F. Y., Jackson, E. T., Pekari, K., and Smith, M. T. (1996b). Population toxicokinetics of benzene. Environ. Health Perspect. 104(Suppl. 6), 1405-1411.
12. Bray, T., Paoli, J., and Sperberg-McQueen, C. M. (1998). Extensible Markup Language (XML) 1.0. Available at: http://www.w3.org/TR/1998/REC-xml-19980210. Accessed May 1, 2011.
13. Chiu, W. A., and Bois, F. Y. (2006). Revisiting the population toxicokinetics of tetrachloroethylene. Arch. Toxicol. 80, 382-385.
14. Chiu, W. A., and Ginsberg, G. L. (2011). Development and evaluation of a harmonized physiologically based pharmacokinetic (PBPK) model for perchloroethylene toxicokinetics in mice, rats, and humans. Toxicol. Appl. Pharmacol. 253, 203-234.
15. Chiu, W. A., Okino, M. S., and Evans, M. V. (2009). Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. Toxicol. Appl. Pharmacol. 241, 36-60.
16. Clewell, H. J. (1995). The use of physiologically based pharmacokinetic modeling in risk assessment: A case study with methylene chloride. In Low-Dose Extrapolation of Cancer Risks: Issues and Perspectives (S. Olin, W. Farland, C. Park, R. Rhomberg, L. Scheuplein, T. Starr, and J. Wilson, Eds.), pp. 199-221. ILSI Press, Washington, DC.
17. Clewell, H. J., III, and Andersen, M. E. (1996). Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 111, 315-329.
18. Clewell, H. J., Gearhart, J. M., Gentry, P. R., Covington, T. R., Van Landingham, C. B., Crump, K. S., and Shipp, A. M. (1999). Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal. 19, 547-558.
19. Clewell, H. J., Gentry, P. R., Covington, T. R., Sarangapani, R., and Teeguarden, J. G. (2004). Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 79, 381-393.
20. Clewell, H. J., III, and Jarnot, B. M. (1994). Incorporation of pharmacokinetics in noncancer risk assessment: Example with chloropentafluorobenzene. Risk Anal. 14, 265-276.
21. Clewell, H. J., Teeguarden, J. G., McDonald, T., Sarangapani, R., Lawrence, G., Covington, T. R., Gentry, P. R., and Shipp, A. M. (2002). Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 32, 329-389.
22. Covington, T. R., Gentry, P. R., Van Landingham, C. B., Andersen, M. E., Kester, J. E., and Clewell, H. J. (2007). The use of Markov chain Monte Carlo uncertainty analysis to support a public health goal for perchloroethylene. Regul. Toxicol. Pharmacol. 47, 1-18.
23. D'Souza, R. W., Francis, W. R., and Andersen, M. E. (1988). Physiological model for tissue glutathione depletion and increased resynthesis after ethylene dichloride exposure. J. Pharmacol. Exp. Ther. 245, 563-568.
24. D'Souza, R. W., Francis, W. R., Bruce, R. D., and Andersen, M. E. (1987). Physiologically based pharmacokinetic model for ethylene dichloride and its application in risk assessment. In Pharmacokinetics in Risk Assessment: Drinking Water and Health, pp. 286-301. National Academy Press, Washington, DC.
25. Daniel, F. B., Robinson, M., Olson, G. R., York, R. G., and Condie, L. W. (1994). Ten and ninety-day toxicity studies of 1,2-dichloroethane in Sprague-Dawley rats. Drug Chem. Toxicol. 17, 463-477.
26. Ennis, M. (2004). ChEBI A Dictionary of Chemical Entities with an Associated Ontology. SOFG-2, Philadelphia, PA, October 23-26, 2004.
27. Evans, M. V., Chiu, W. A., Okino, M. S., and Caldwell, J. C. (2009). Development of an updated PBPK model for trichloroethylene and metabolites in mice, and its application to discern the role of oxidative metabolism in TCEinduced hepatomegaly. Toxicol. Appl. Pharmacol. 236, 329-340.
28. Gentry, P. R., Hack, C. E., Haber, L., Maier, A., and Clewell, H. J., III (2002). An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: Examples with warfarin and parathion. Toxicol. Sci. 70, 120-139.
29. Gruber, T. R. (1995). Toward principles for the design of ontologies used for knowledge sharing. Int. J. Hum.-Comput. St. 43, 907-928.
30. Gruber, T. R., Tenenbaum, J. M., and Weber, J. C. (1992). Toward a knowledge medium for collaborative product development. In Artificial Intelligence in Design (J. S. Gero, Ed.), pp. 413-432. Kluwer Academic Publishers, Boston, MA.
31. Haber, L. T., Maier, A., Gentry, P. R., Clewell, H. J., and Dourson, M. L. (2002). Genetic polymorphisms in assessing interindividual variability in delivered dose. Regul. Toxicol. Pharmacol. 35, 177-197.
32. Hucka, M., Finney, A., Sauro, H. M., Bolouri, H., Doyle, J. C., Kitano, H., Arkin, A. P., Bornstein, B. J., Bray, D., Cornish-Bowden, A., et al. (2003). The systems biology markup language (SBML): A medium for representation and exchange of biochemical network models. Bioinformatics 19, 524-531.
33. Johanson, G., Jonsson, F., and Bois, F. Y. (1999). Development of new technique for risk assessment using physiologically based toxicokinetic models. Am. J. Ind. Med. 36(Suppl 1), 101-103.
34. Jonsson, F., Bois, F. Y., and Johanson, G. (2001a). Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicol. Sci. 59, 209-218.
35. Jonsson, F., Bois, F. Y., and Johanson, G. (2001b). Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects. Arch. Toxicol. 75, 189-199.
36. Jonsson, F., and Johanson, G. (2001a). A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicol. Appl. Pharmacol. 174, 99-112.
37. Jonsson, F., and Johanson, G. (2001b). Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic Modeling of inhalation exposure to toluene. Toxicology 157, 177-193.
38. Kopylev, L., Chen, C., and White, P. (2007). Towards quantitative uncertainty assessment for cancer risks: Central estimates and probability distributions of risk in dose-response modeling. Regul. Toxicol. Pharmacol. 49, 203-207.
39. Lipscomb, J. C., Teuschler, L. K., Swartout, J., Popken, D., Cox, T., and Kedderis, G. L. (2003). The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Anal. 23, 1221-1238.
40. Makalowski, W. (2000). Genomic scrap yard: How genomes utilize all that junk. Gene 259, 61-67.
41. Marino, D. J., Clewell, H. J., Gentry, P. R., Covington, T. R., Hack, C. E., David, R. M., and Morgott, D. A. (2006). Revised assessment of cancer risk to dichloromethane: Part I Bayesian PBPK and dose-response modeling in mice. Regul. Toxicol. Pharmacol. 45, 44-54.
42. McGuinness, D. L., and van Harmelen, F. (2004). OWL Web Ontology Language Overview, W3C Recommendation, 10 February 2004, Web Ontology Working Group. Available at: http://www.w3.org/TR/owl-features/. Accessed May 2, 2011.
43. National Research Council (NRC). (1994). Science and Judgment in Risk Assessment. National Academy Press, Washington, DC.
44. Portier, C. J., and Kaplan, N. L. (1989). Variability of safe dose estimates when using complicated models of the carcinogenic process. A case-study: Methylene chloride. Fundam. Appl. Toxicol. 13, 533-544.
45. Price, P.S., Conolly, R. B., Chaisson, C.F., Gross, E.A., Young, J. S., Mathis, E. T., and Tedder, D. R. (2003). Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 33, 469-503.
46. Qiu, J., Chien, Y. C., Bruckner, J. V., and Fisher, J. W. (2010). Bayesian analysis of a physiologically based pharmacokinetic model for perchloroethylene in humans. J. Toxicol. Environ. Health A 73, 74-91.
47. Renwick, A. G. (1994). Toxicokinetics-pharmacokinetics in toxicology. In Principles and Methods of Toxicology (E. W. A. Hayes, Ed.), pp. 101-147. Raven Press, New York, NY.
48. Schmidt, H., and Jirstrand, M. (2006). Systems biology toolbox for MATLAB: A computational platform for research in systems biology. Bioinformatics 22, 514-515.
49. Sweeney, L. M., Gargas, M. L., Strother, D. E., and Kedderis, G. L. (2003). Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. Toxicol. Sci. 71, 27-40.
50. Sweeney, L. M., Kirman, C. R., Gargas, M. L., and Dugard, P. H. (2009). Contribution of trichloroacetic acid to liver tumors observed in perchloroethylene (perc)-exposed mice. Toxicology 260, 77-83.
51. Sweeney, L. M., Saghir, S. A., and Gargas, M. L. (2008). Physiologically based pharmacokinetic model development and simulations for ethylene dichloride (1,2-dichloroethane) in rats. Regul. Toxicol. Pharmacol. 51, 311-323.
52. Timchalk, C., Nolan, R. J., Mendrala, A. L., Dittenber, D. A., Brzak, K. A., and Mattsson, J. L. (2002). A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol. Sci. 66, 34-53.
53. U.S. Environmental Protection Agency (EPA). (2003a). 1,2-Ethylene dichloride: Final Enforceable Consent Agreement and Testing Consent Order. Washington, DC. 68 FR 33125 (May 13, 2003).
54. U.S. Environmental Protection Agency (EPA). (2003b). 1,1,2-Trichloroethane (TCE); EPA Program Review: Notice of Availability. Washington, DC. 68 FR 40944 (July 9, 2003).
55. U.S. Environmental Protection Agency (EPA). (2006). Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment (Final Report). Washington, DC. EPA/ 600/R-05/043F.
56. U.S. Environmental Protection Agency (EPA). (2011). Integrated Risk Information System (IRIS) Glossary. Available at: http://www.epa.gov/iris/help_gloss.htm. Accessed May 13, 2011.
57. Wagner, J. G. (1981). History of pharmacokinetics. Pharmacol. Ther. 12, 537-562.
58. World Health Organization. (2010). International Programme on Chemical Safety Harmonization Project. Characterization and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment. Harmonization Project Document No. 9. World Health Organization, Geneva, Switzerland.